Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03148418




Registration number
NCT03148418
Ethics application status
Date submitted
9/05/2017
Date registered
11/05/2017
Date last updated
12/08/2024

Titles & IDs
Public title
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Scientific title
An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study
Secondary ID [1] 0 0
2016-005189-75
Secondary ID [2] 0 0
BO39633
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cancer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Bevacizumab

Experimental: Atezolizumab Monotherapy - Participants will continue to receive atezolizumab monotherapy in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.

Experimental: Combined Agents with Atezolizumab - Participants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.

Active comparator: Comparator Treatment - Participants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.


Treatment: Drugs: Atezolizumab
Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).

Treatment: Drugs: Bevacizumab
Bevacizumab will be administered as directed per the parent study.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)
Timepoint [1] 0 0
Day 1 up to maximum 10 years
Secondary outcome [1] 0 0
Percentage of Participants With Serious Adverse Events (SAEs) by Severity Determined According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
Timepoint [1] 0 0
Day 1 up to 90 days after last dose of study treatment (last dose=till clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)
Secondary outcome [2] 0 0
Percentage of Participants With Adverse Events of Special Interest by Severity Determined According to NCI CTCAE Version 4.0
Timepoint [2] 0 0
Day 1 up to 90 days after last dose of study treatment (last dose=till clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)
Secondary outcome [3] 0 0
Time from Randomization or Treatment Initiation to Death due to any Cause for IMpower133 Participants Only
Timepoint [3] 0 0
Day 1 (as indicated in parent study protocol) until death due to any cause (up to maximum 10 years)

Eligibility
Key inclusion criteria
Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study (and survival follow up for pattients who roll over from IMpower133):

* Eligible for continuing or crossing over to atezolizumab-based therapy at the time of the parent-study closure as per the parent study or eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the parent-study closure as per the parent study, with no access to commercially available comparator agent
* First dose of study treatment in the extension study will be received within 7 days of the treatment interruption window allowed by the parent study
* Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of parent-study closure as assessed by the investigator
* Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential

Specific criteria for patients from the IMpower133 parent study only who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:

- Discontinuation of atezolizumab-based therapy in the IMpower133 parent study and in survival follow- up at the time of IMpower133 parent study closure, or eligible for continuing or crossing over to atezolizumab-based therapy as per the IMpower133 parent protocol and have access to commercially available atezolizumab (Tecentriq) outside this extension study at the time of the IMpower133 parent-study closure
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study:

* Meet of any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in the extension study
* Study treatment is commercially marketed in the patient's country for the patient specific disease and is accessible to the patient
* Time between the last dose of treatment received in parent study and first dose in extension study is longer than the interruption period (± 7 days) allowed in the parent study
* Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in the extension study
* Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study (if applicable)
* Any unresolved or irreversible toxicities during the parent study that required permanent discontinuation of study treatment, in accordance to the parent study or local prescribing information
* Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to (<=) 1 from the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study
* Any serious uncontrolled concomitant disease that would contraindicate the use of study treatment at the time of the extension study or that would place the participant at high risk for treatment-related complications
* Concurrent participation in any therapeutic clinical trial (other than the parent study)

Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:

- Discontinuation of comparator in parent study and in survival follow-up at the time of parent study closure

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/09/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
6/03/2030
Actual
Sample size
Target
Accrual to date
Final
382
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
Princess AleXandra Hospital; Department of Medical Oncology - Woolloongabba
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Maine
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nevada
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
Argentina
State/province [26] 0 0
Buenos Aires
Country [27] 0 0
Austria
State/province [27] 0 0
Wien
Country [28] 0 0
Belgium
State/province [28] 0 0
Ronse
Country [29] 0 0
Belgium
State/province [29] 0 0
Wilrijk
Country [30] 0 0
Brazil
State/province [30] 0 0
SP
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Sofia
Country [32] 0 0
Canada
State/province [32] 0 0
Ontario
Country [33] 0 0
Canada
State/province [33] 0 0
Quebec
Country [34] 0 0
Chile
State/province [34] 0 0
Recoleta
Country [35] 0 0
Czechia
State/province [35] 0 0
Brno
Country [36] 0 0
Czechia
State/province [36] 0 0
Praha 4 - Krc
Country [37] 0 0
France
State/province [37] 0 0
Besancon
Country [38] 0 0
France
State/province [38] 0 0
Grenoble
Country [39] 0 0
France
State/province [39] 0 0
Lyon
Country [40] 0 0
France
State/province [40] 0 0
Marseille
Country [41] 0 0
France
State/province [41] 0 0
Nantes
Country [42] 0 0
France
State/province [42] 0 0
Nice
Country [43] 0 0
France
State/province [43] 0 0
Paris
Country [44] 0 0
France
State/province [44] 0 0
Pierre Benite
Country [45] 0 0
France
State/province [45] 0 0
Saint Quentin
Country [46] 0 0
France
State/province [46] 0 0
Suresnes
Country [47] 0 0
France
State/province [47] 0 0
Toulouse cedex 9
Country [48] 0 0
France
State/province [48] 0 0
VILLEJUIF Cedex
Country [49] 0 0
Germany
State/province [49] 0 0
München
Country [50] 0 0
Hungary
State/province [50] 0 0
Budapest
Country [51] 0 0
Hungary
State/province [51] 0 0
Törökbálint
Country [52] 0 0
Israel
State/province [52] 0 0
Petah Tikva
Country [53] 0 0
Italy
State/province [53] 0 0
Campania
Country [54] 0 0
Italy
State/province [54] 0 0
Emilia-Romagna
Country [55] 0 0
Italy
State/province [55] 0 0
Lazio
Country [56] 0 0
Italy
State/province [56] 0 0
Liguria
Country [57] 0 0
Italy
State/province [57] 0 0
Lombardia
Country [58] 0 0
Italy
State/province [58] 0 0
Piemonte
Country [59] 0 0
Italy
State/province [59] 0 0
Sicilia
Country [60] 0 0
Italy
State/province [60] 0 0
Toscana
Country [61] 0 0
Italy
State/province [61] 0 0
Umbria
Country [62] 0 0
Italy
State/province [62] 0 0
Veneto
Country [63] 0 0
Japan
State/province [63] 0 0
Ehime
Country [64] 0 0
Japan
State/province [64] 0 0
Iwate
Country [65] 0 0
Japan
State/province [65] 0 0
Miyagi
Country [66] 0 0
Japan
State/province [66] 0 0
Niigata
Country [67] 0 0
Japan
State/province [67] 0 0
Okayama
Country [68] 0 0
Japan
State/province [68] 0 0
Tokyo
Country [69] 0 0
Japan
State/province [69] 0 0
Wakayama
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Goyang-si
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Jeollanam-do
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Seongnam-si
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Seoul
Country [74] 0 0
Netherlands
State/province [74] 0 0
Amsterdam
Country [75] 0 0
New Zealand
State/province [75] 0 0
Auckland
Country [76] 0 0
Poland
State/province [76] 0 0
Gdansk
Country [77] 0 0
Poland
State/province [77] 0 0
Warszawa
Country [78] 0 0
Portugal
State/province [78] 0 0
Lisboa
Country [79] 0 0
Portugal
State/province [79] 0 0
Porto
Country [80] 0 0
Romania
State/province [80] 0 0
Cluj-napoca
Country [81] 0 0
Romania
State/province [81] 0 0
Timisoara
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Moskovskaja Oblast
Country [83] 0 0
Serbia
State/province [83] 0 0
Belgrade
Country [84] 0 0
Slovenia
State/province [84] 0 0
Ljubljana
Country [85] 0 0
Spain
State/province [85] 0 0
Barcelona
Country [86] 0 0
Spain
State/province [86] 0 0
Cordoba
Country [87] 0 0
Spain
State/province [87] 0 0
Islas Baleares
Country [88] 0 0
Spain
State/province [88] 0 0
LAS Palmas
Country [89] 0 0
Spain
State/province [89] 0 0
Navarra
Country [90] 0 0
Spain
State/province [90] 0 0
Caceres
Country [91] 0 0
Spain
State/province [91] 0 0
Jaen
Country [92] 0 0
Spain
State/province [92] 0 0
La Coruña
Country [93] 0 0
Spain
State/province [93] 0 0
Lugo
Country [94] 0 0
Spain
State/province [94] 0 0
Madrid
Country [95] 0 0
Spain
State/province [95] 0 0
Malaga
Country [96] 0 0
Spain
State/province [96] 0 0
Sevilla
Country [97] 0 0
Spain
State/province [97] 0 0
Valencia
Country [98] 0 0
Switzerland
State/province [98] 0 0
Lausanne
Country [99] 0 0
Taiwan
State/province [99] 0 0
Changhua
Country [100] 0 0
Taiwan
State/province [100] 0 0
Taichung
Country [101] 0 0
Taiwan
State/province [101] 0 0
Taipei
Country [102] 0 0
Thailand
State/province [102] 0 0
Bangkok
Country [103] 0 0
Turkey
State/province [103] 0 0
Edirne
Country [104] 0 0
Turkey
State/province [104] 0 0
Istanbul
Country [105] 0 0
Turkey
State/province [105] 0 0
Sihhiye/Ankara
Country [106] 0 0
Ukraine
State/province [106] 0 0
Podolia Governorate
Country [107] 0 0
Ukraine
State/province [107] 0 0
Dnipropetrovsk
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Liverpool
Country [109] 0 0
United Kingdom
State/province [109] 0 0
London
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Manchester
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Nottingham
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03148418